Neuropeptide Y and Asthma Clinical Course

Abstract

Background: The spectrum of clinical manifestations and pathogenetic mechanisms of bronchial asthma (BA) is very wide. Given the complex pathogenesis and syndromic nature of BA, it is not surprising that there is no single universal biomarker. The objective of this study was to evaluate levels of neuropeptide Y (NPY) and its association with levels of leptin, adiponectin, oxidative damage, antioxidant status, spirometry parameters, and asthma control in BA patients. Methods and Results: Overall, 140 patients [35(25%) men and 105(75%) women; mean age of 57.0±9.34 years] with moderate asthma participated in the study. According to body mass index, all patients were divided into three groups. The asthma diagnosis was based on the integral assessment of symptoms, medical history, health status, and spirometry values according to the Global Strategy for Asthma Management and Prevention. (GINA, 2017 REPORT). The Asthma Control Test (АСТ) was used to assess asthma control. NPY was measured in blood serum in EIA. The NPY level was significantly higher in overweight patients and patients with obesity than in patients with normal body weight. The NPY level significantly correlated with leptin (r=0.44; P<0.05), adiponectin (r=-0.24; P<0.05), ImanOx (r=-0.40; P<0.05), PerOx (r=0.58; P<0.05), ACT (r=-0.41; P<0.05), VC (r=-0.31; P<0.05), FEV1 (r=-0.41; P<0.05), FEF25% (r=-0.26; P<0.05), FVC (r=-0.23; P<0.05), Tiffno index (r=-0.36; P<0.05), FEF50% (r=-0.22; P<0.05), and PEF (r=-0.23; P<0.05) Conclusion: The severity of the asthma clinical course is associated with different factors, including oxidative stress, levels of leptin, adiponectin and NPY. NPY seems to be associated with worse asthma control and higher levels of leptin and oxidative damage.